Date | News item |
2012 | Work starts to screen and optimize dietary bioactive compounds for induction of Glo1 expression – Healthy Aging Through Functional Food (HATFF or Hats-off) project. |
2015 | PCT priority patent application file on Glo1 inducers. |
2016 | Peer-reviewed publication on outcome of Healthy Aging Through Functional Food (HATFF or Hats-off) clinical trial study showing Glo1 inducer corrects insulin resistance and improves metabolic and vascular health in overweight and obese subjects. |
Three presentations at 52nd Annual Meeting of the European Association For the Study of Diabetes (EASD), Munich, Germany on Glo1 inducer improvement of glycemic and vascular health. |
2017 | Presentation at the 69th American Association of Clinical Chemists Annual Scientific Meeting & Clinical Lab Expo, San Diego, USA, on protein glycation and Glo1 inducer therapeutics |
Presentation at the American Diabetes Association 77th Scientific Sessions, San Diego, USA, on protein glycation and Glo1 inducer therapeutics |
Presentation at the 53rd Annual Meeting of the European Association For the Study of Diabetes (EASD), Lisbon, Portugal, on protein glycation and Glo1 inducer therapeutics |
2018 | Conference presentation on Glo1 inducer prevention of endothelial dysfunction in hyperglycemia at 54th Annual Meeting of the European Association For the Study of Diabetes (EASD), Berlin, Germany |
2019 | Presentation at the 79th American Diabetes Association Scientific Sessions, San Francisco, USA, on Glo1 inducer correcting metabolic dysfunction in hyperglycemia |
Peer-reviewed publication on Glo1 inducer corrects endothelial cell dysfunction in model hyperglycemia. |
2020 | Peer-reviewed publication on Glo1 inducer corrects fibroblast dysfunction in hyperglycemia. |
2021 | Peer-reviewed publication on link of Glo1 inducer treatment to improvement of dysglycemia, blood pressure, dyslipidemia and low-grade inflammation in the HATFF study. |
Presentation at the International Diabetes Federation Virtual Conference on Diabetic Complications on Glo1 inducer is a prospective new treatment for vascular complications of diabetes |
2022 | Glocentrica Ltd takes ownership of Glo1 inducer patents in USA and Europe |
2023 | European Patent Office grants patent on Glo1 inducer to Glocentrica Ltd |
Peer-reviewed paper on how decreased methylglyoxal-modified protein is linked to healthy aging in a mouse model |
2024 | Peer-reviewed paper on methylglyoxal and methylglyoxal-modified proteins are major physiological activators of the unfolded protein response (UPR), prevented by Glo1 inducer. |
Peer-reviewed paper on “Hexokinase-linked glycolytic overload and unscheduled glycolysis” explains how Glo1 inducer improves glycemic health. |